Supreme Court E-Library
Information At Your Fingertips


  View printer friendly version

(NAR) VOL. 23 NO. 1, JANUARY - MARCH 2012)

[ FDA CIRCULAR NO. 2011-003-A, July 07, 2011 ]

REVISION TO THE SCHEDULE OF FEES LISTED IN FDA CIRCULAR NO. 2011-003 DATED 24 JUNE 2011 ON THE COLLECTION OF LEGAL RESEARCH FEE IMPOSED BY REPUBLIC ACT NO. 3870, AS AMENDED BY PD 200 AND FURTHER AMENDED BY PD 1856



Below is the revision to the Schedule of Fees listed in FDA Circular No. 2011-003 incorporating the corrections to the affected services and their corresponding Fee and Legal Research Fee.

A. Licensing of Establishment (In page 4)
 
  
AO 50, s. 2001
  
Initial
Renewal
Fees for Licensing of Establishment
Fee
LRF
Total
Fee
LRF
Total
16. Others        
 16.2 Clearance to Import Antibiotics 
300.00
10.00
310.00
    
 16.3 Amendment of LTO or Re-Issuance
500.00
10.00
510.00
    

B. Product Registration (In Pages 5 & 6)
 
1. Drugs
              
1.1 New Drug/Monitored Release
20,000.00
200.00
20,200.00
        
7.5 Re-Issuance of CPR (Lost Reconstruction)
300.00
10.00
310.00
        
    7.8.3 Review by ACB
    g. Protocol Amendment
    h. Extension of Monitored Release
    i. Compassionate Special Permit except drugs for cancer, HIV/AIDS, and other life threatening diseases)
       
1,000.00
10.00
1,010.00
        
6,000.00
60.00
6,060.00
        
500.00
10.00
510.00
        


C. Laboratory Analysis (In Page 7)
 
CLASSIFICATION
       
1.1 Drugs       
 Vitamins       
  Vitamin C ( Ascorbic Acid)
500.00
10.00
510.00
    

Adopted: 07 July 2011


(SGD.) SUZETTE H. LAZO, M.D., FPSECP
Acting Director IV
© Supreme Court E-Library 2019
This website was designed and developed, and is maintained, by the E-Library Technical Staff in collaboration with the Management Information Systems Office.